Home › Medical › Cannabis Withdrawal and Sleep Disruption
⚐ Flag an error How this page was made
Also known as: CWS sleep disruption · cannabis withdrawal insomnia · cannabinoid hyperemesis sleep symptoms

Cannabis Withdrawal and Sleep Disruption

Sleep disruption is a hallmark of cannabis withdrawal syndrome and typically resolves within weeks with proper support.

Automated fact-check pass
18 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Cannabis withdrawal insomnia is real, miserable, and temporary—but it's not permanent or medically dangerous. The best evidence supports time, expectation-setting, and CBT-I. Most other treatments either lack solid proof or trade one problem for another (benzodiazepines, alcohol). Gabapentin and pharmaceutical THC have some data but aren't yet standard care. Melatonin and sleep hygiene are low-risk to try. Pushing through without support causes relapse in most people.

Plain-Language Summary

When someone who uses cannabis regularly—especially daily—stops, the body goes through a withdrawal process. Cannabis Withdrawal Syndrome (CWS) is recognized in both the DSM-5 and ICD-11 [1][2]. Sleep disruption is one of its most consistent features, alongside irritability, anxiety, decreased appetite, and restlessness Strong evidence[3].

The specific sleep problems include trouble falling asleep, frequent waking, reduced total sleep time, and unusually vivid or disturbing dreams [4][5]. The dream intensity reflects a rebound in REM sleep, which chronic THC use suppresses Strong evidence[4][6].

Symptoms typically start within 1–3 days of stopping, peak in the first week, and resolve within 2–3 weeks. Sleep problems specifically can linger longer than mood or appetite symptoms—sometimes 4–6 weeks in heavy users [3][5] Strong evidence.

This article is informational only and is not medical advice. If you're trying to stop cannabis use and sleep problems are severe, or you're considering other substances to cope, talk to a clinician.

What the Science Shows Works

Expectation-Setting and Understanding CWS as Temporary

Knowing that withdrawal symptoms are predictable and time-limited reduces relapse compared to interpreting insomnia as a permanent problem Strong evidence[3]. This is not a treatment per se, but a framework that improves outcomes.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is first-line treatment for chronic insomnia in general and is recommended by the American College of Physicians and American Academy of Sleep Medicine [7][8]. Its mechanisms—stimulus control, sleep restriction, addressing catastrophic thinking about sleep—directly address the patterns that drive relapse during withdrawal Weak / limited. It has not been heavily tested in CWS specifically, but the underlying principles apply Weak / limited.

Moderate Aerobic Exercise

Regular daytime exercise improves sleep onset and slow-wave sleep in the general population Strong evidence[9]. It also helps with mood symptoms of withdrawal Weak / limited. A daily 30-minute walk or jog is low-cost and has no downside risk.

Basic Sleep Hygiene

Consistent wake time, cool dark room, no screens one hour before bed, no caffeine after early afternoon—these are modest in individual effect but uncontroversial and cost-free Weak / limited.

Treatments with Emerging or Mixed Evidence

Gabapentin

One randomized trial (n~100) found gabapentin reduced cannabis withdrawal symptoms including sleep problems compared to placebo [10] Weak / limited. The mechanism is unclear but may involve GABA modulation. Cost and side effects (dizziness, sedation) must be weighed against the temporary nature of CWS. A repeat trial would strengthen evidence.

Pharmaceutical Cannabinoids (Dronabinol, Nabiximols)

Several randomized trials show that giving cannabis-dependent patients oral THC (dronabinol) or THC/CBD spray (nabiximols) during a quit attempt reduces withdrawal severity, including sleep disruption Weak / limited[11][12]. This is essentially a slow taper rather than abrupt cessation. Nabiximols is licensed for this use in Canada and parts of Europe; neither is FDA-approved for CWS in the US. Relapse risk during and after taper requires careful monitoring.

Mirtazapine

One small trial in heavy cannabis users found mirtazapine improved sleep during withdrawal Weak / limited[13]. Mirtazapine is a tetracyclic antidepressant with antihistamine properties that causes sedation and weight gain—potentially addressing two withdrawal symptoms at once. However, it carries anticholinergic effects and is not first-line for transient insomnia.

Melatonin

Melatonin has a plausible mechanism for sleep onset. General insomnia data is mixed; no good trials exist in CWS specifically Weak / limited. Low cost, low overdose risk, and available over-the-counter make it reasonable to try at standard doses (0.5–3 mg before bed), though outcomes are inconsistent.

CBD

Popular online but the evidence for CBD improving sleep is thin. High-dose studies show modest effects on anxiety-related insomnia, but most over-the-counter products are far below those doses and inconsistently labeled Weak / limited[14]. Link: CBD and Sleep.

What Does Not Work or Carries Risk

No Support or "Just Push Through"

Unsupported quit attempts in daily users have low 6-month abstinence rates Strong evidence[3]. Relapse is common and driven partly by insomnia.

Alcohol as a Sleep Aid

Alcohol disrupts sleep architecture, increases waking in the second half of the night, and risks substituting one substance use disorder for another Strong evidence[15].

Over-the-Counter Antihistamines (Diphenhydramine, Doxylamine)

These sedating antihistamines cause grogginess the next day, tolerance develops quickly within days, and long-term use is associated with worse sleep quality despite faster onset Weak / limited.

Benzodiazepines and Z-Drugs (Zolpidem, Zaleplon)

Effective short-term for sleep but trade one dependence for another with a more severe withdrawal profile. Not appropriate for CWS treatment Strong evidence.

Kratom and Herbal Sleep Blends

No controlled evidence for CWS. Kratom in particular carries its own dependence and withdrawal syndrome risk [16].

Returning to Cannabis "Just to Sleep"

This works the same night but restarts dependence and guarantees the same withdrawal next time you stop Strong evidence.

What We Don't Know

Comparison with Standard Insomnia Treatment

Standard chronic insomnia care per the American Academy of Sleep Medicine and American College of Physicians is CBT-I first, then short-term pharmacotherapy if needed [7][8]. For CWS-related insomnia, the same hierarchy applies, with two key caveats:

Time-limited course. Unlike chronic primary insomnia, CWS insomnia resolves on its own in 2–6 weeks. The goal is to bridge that period, not manage indefinitely. This argues against starting long-term medications like selective serotonin reuptake inhibitors.

Underlying substance use disorder. Pure sleep treatment without addressing cannabis use will fail if the person resumes daily use. Integrated care—sleep support plus motivational interviewing or contingency management for cannabis dependence—outperforms either alone Weak / limited[18].

Risks and When to See a Clinician

CWS itself is not medically dangerous—unlike alcohol or benzodiazepine withdrawal, it does not cause seizures, delirium, or cardiovascular instability Strong evidence. The main risks are:

Relapse driven by insomnia. Most common adverse outcome and reason for treatment failure.

Substitution with worse substances. Alcohol, benzodiazepines, and opioids carry higher dependence and overdose risk than cannabis.

Emergent or worsening mood symptoms. Depression, anxiety, and suicidal ideation can emerge or intensify during withdrawal in vulnerable people Weak / limited[3]. This is the most important reason to involve a clinician if symptoms are severe.

Misdiagnosis. Pre-existing insomnia, sleep apnea, or anxiety disorder may have been masked by cannabis use and become visible after quitting. These need independent workup.

Seek clinician input if:

Sources

  1. Book American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Cannabis Withdrawal, pp. 517–519.
  2. Government World Health Organization. ICD-11 for Mortality and Morbidity Statistics. Cannabis withdrawal (6C41.4).
  3. Peer-reviewed Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161(11), 1967–1977.
  4. Peer-reviewed Bolla, K. I., Lesage, S. R., Gamaldo, C. E., et al. (2008). Sleep disturbance in heavy marijuana users. Sleep, 31(6), 901–908.
  5. Peer-reviewed Allsop, D. J., Copeland, J., Norberg, M. M., et al. (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS ONE, 7(9), e44864.
  6. Peer-reviewed Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020). Sleep, insomnia, and depression. Neuropsychopharmacology, 45(1), 74–89.
  7. Peer-reviewed Qaseem, A., Kansagara, D., Forciea, M. A., et al. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133.
  8. Peer-reviewed Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349.
  9. Peer-reviewed Kredlow, M. A., Capozzoli, M. C., Hearon, B. A., Calkins, A. W., & Otto, M. W. (2015). The effects of physical activity on sleep: a meta-analytic review. Journal of Behavioral Medicine, 38(3), 427–449.
  10. Peer-reviewed Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37(7), 1689–1698.
  11. Peer-reviewed Allsop, D. J., Copeland, J., Lintzeris, N., et al. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry, 71(3), 281–291.
  12. Peer-reviewed Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011). Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 116(1–3), 142–150.
  13. Peer-reviewed Haney, M., Hart, C. L., Vosburg, S. K., et al. (2010). Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 211(2), 233–244.
  14. Peer-reviewed Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: a large case series. The Permanente Journal, 23, 18–041.
  15. Government U.S. Food and Drug Administration. FDA and Kratom—safety communications and warnings.
  16. Peer-reviewed Ebrahim, I. O., Shapiro, C. M., Williams, A. J., & Fenwick, P. B. (2013). Alcohol and sleep I: effects on normal sleep. Alcoholism: Clinical and Experimental Research, 37(4), 539–549.
  17. Peer-reviewed Copeland, J., Pokorski, I., & Swift, W. (2013). Cannabis withdrawal: what we have learned from research. Drugs, 73(14), 1479–1491.
  18. Peer-reviewed Budney, A. J., Stanger, C., Knapp, A. A., & Walker, D. D. (2021). Status update on the treatment of cannabis use disorder. Substance Abuse, 42(3), 248–256.

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 29, 2026
Fact-check pass — raised 11 flags
Jun 14, 2026
Self-review — raised 2 flags
May 11, 2026
Fact-check pass — raised 3 flags
May 11, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.